AstraZeneca, Imperial College to partner on RNA technology
Published
Sep 23 2021 at 7:52 AM GMT
Key
Points
Points
- AstraZeneca has teamed up with a startup from Imperial College London to expand disease fighting beyond COVID-19 using next generation messenger RNA technology.
- That's according to the professor leading Imperial's research, Robin Shattock, who made the comments in an interview with Bloomberg that published on Thursday.
- The partnership between Imperial and AstraZeneca, will focus on cancers and infectious and respiratory diseases using an approach called self-amplifying RNA, which aims to create a strong and steady immune response with a smaller dose.
- The startup --- VaxEquity --- will get a "sizeable" investment from AstraZeneca, said Shattock.
- Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.
Trending
Stats
- Published Sep 23, 2021 7:52 AM GMT